Bruker (NASDAQ:BRKR) Stock Price Up 3.9% – Time to Buy?

Bruker Corporation (NASDAQ:BRKR)’s stock price rose 3.9% on Tuesday . The company traded as high as $54.99 and last traded at $54.7180. 291,047 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 2,341,848 shares. The stock had previously closed at $52.66.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on BRKR. Guggenheim upped their target price on Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. TD Cowen reaffirmed a “hold” rating on shares of Bruker in a report on Wednesday, July 15th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a research report on Monday, August 31st. Stifel Nicolaus set a $50.00 target price on shares of Bruker in a research note on Wednesday, August 5th. Finally, Wolfe Research assumed coverage on Bruker in a research note on Monday, June 1st. They issued a “peer perform” rating for the company. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $57.00.

Bruker Stock Up 4.4%

The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. The business’s 50 day moving average price is $58.07 and its 200 day moving average price is $49.41. The firm has a market cap of $8.38 billion, a PE ratio of -78.63, a PEG ratio of 1.63 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.11. The company had revenue of $838.50 million for the quarter, compared to analysts’ expectations of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.Bruker’s revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities research analysts expect that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be paid a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 21st. Bruker’s dividend payout ratio (DPR) is currently -28.57%.

Institutional Investors Weigh In On Bruker

A number of large investors have recently made changes to their positions in the stock. Pallas Capital Advisors LLC acquired a new position in shares of Bruker in the 2nd quarter worth approximately $570,746,000. Sculptor Capital LP grew its stake in shares of Bruker by 9.0% in the first quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company’s stock valued at $118,112,000 after buying an additional 270,000 shares in the last quarter. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of Bruker in the 2nd quarter valued at $169,899,000. Dimensional Fund Advisors LP lifted its stake in Bruker by 23.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,341,518 shares of the medical research company’s stock worth $84,556,000 after acquiring an additional 448,440 shares in the last quarter. Finally, Franklin Resources Inc. boosted its holdings in Bruker by 317.7% during the 4th quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock valued at $108,796,000 after acquiring an additional 1,756,460 shares during the period. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.